Eli Lilly Corp. diskutieren

Eli Lilly and Company (NYSE: LLY) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $1,000.00 price target on the stock, up previously from $892.00.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $1,001.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $1,023.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Barclays PLC from $913.00 to $1,025.00. They now have an "overweight" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $900.00 to $1,000.00. They now have an "overweight" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Berenberg Bank from $850.00 to $1,000.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Guggenheim from $855.00 to $884.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Bank of America Co. from $1,000.00 to $1,125.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Wells Fargo & Company from $875.00 to $1,000.00. They now have an "overweight" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Berenberg Bank from $1,000.00 to $1,050.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at Guggenheim from $884.00 to $1,030.00. They now have a "buy" rating on the stock.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $1,106.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $885.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $1,060.00 price target on the stock.

Eli Lilly and Company (NYSE: LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,050.00 to $1,100.00. They now have an "overweight" rating on the stock.

Man, Eli Lilly is on fire lately! They just got FDA approval for EBGLYSS, their new eczema treatment, which could be a game-changer. And they're pouring billions into expanding manufacturing - talk about confidence in their pipeline! With their obesity and diabetes drugs crushing it, and more promising candidates in the works, Lilly seems to be firing on all cylinders. The stock's had a great run already, but I think there's still room to grow. It ain't cheap, but quality rarely is. I'd say Lilly's worth a look for anyone wanting exposure to a top-tier pharma innovator.